LinkedIn Icon Twitter Icon
March 19-21, 2019 | Boston, MA

Speakers

Expand/Collapse

Sarah McWhirter
Director – Sting Program
Aduro Biotech

Day One

March 20, 2019

16.00 | Discover how Utilisation of the STING pathway has Bolstered the Effectiveness of PD-L1

Jeremy Graff
Chief Scientific Officer and Senior Vice President, Research
Biothera

Dr. Graff has devoted his career to understanding the molecular and cellular underpinnings of malignancy and metastatic progression and then to leverage that expertise to deliver novel anti-cancer therapeutics. He spent more than 20 years in Big Pharma (Eli Lilly and Company) and biotech (Biothera Pharmaceuticals, Inc) working to develop a broad range of anti-cancer therapies including kinase and protein synthesis inhibitors, nuclear hormone receptor modulators and, most recently, innate immune cell activators.  Over the last 10-plus years, he has focused on Translational Oncology, working at the interface of preclinical discovery and clinical development to meld deep mechanistic insight for a drug’s action with robust, mechanism-based patient selection strategies to enhance the probability of a molecule’s clinical and regulatory success. He holds numerous patents and has published more than 60 research manuscripts garnering more than 18000 research citations. He has served as a grant review panelist for the American Cancer Society, NIH/NIDDK, Department of Defense and Genome Quebec. He is also an editor for the journal Cancer Research.  

Day Two

March 21, 2019

14.45 | Panel Discussion – How Can We Sort Through the Huge Number of Trials that are Currently Active?

08.40 | Re-Training Innate Immunity: Combining the Novel Beta Glucan, Imprime PGG, with Checkpoint Inhibitors to Drive a Robust, Coordinated Anti-Cancer Immune Response

Jochem Gokelmeijer
Associate Director
Bristol-Myers Squibb

Mark Paris
Director - Translational Applications
Mitra Biotech

Day One

March 20, 2019

12.00 | A Clinically-Predictive Ex-Vivo Tumor Modelling Platform for Drug Discovery and Development

Mithun Khattar
Scientist & Immuno-oncology lead
Takeda

Workshop A

MARCH 19, 2019

09.00 | Pre-Clinical Development Challenges in Checkpoint Modulators and IO Combinations

Osama Rahma
Assistant Professor
Dana-Faber Cancer Center

Patrick Holder
Scientist
Genentech

Day Two

March 21, 2019

09.40 | Panel Discussion: Mind the Gap - Considering New Targets from Biological Rationale to Therapeutic Protein Delivery

Paul Moore
Vice President - Cell Biology & Immunology
Macrogenics

Day Two

March 21, 2019

14.15 | PD-1-Based Bispecific Antibody Therapies

13.15 | PD-1-Based Bispecific Antibody Therapies

Raphael Clynes
Vice President - Translational Biology
Xencor

Day Two

March 21, 2019

09.10 | T Cell Engagers, Checkpoints and Cytokines to Broaden Immune Responses to Cancer

Shanthi Ganesh
Associate Director
Dicerna Pharmaceuticals

Stephen Doberstein
Senior Vice President - Research, Chief Scientific Officer, Chief Research & Development Officer
Nektar Therapeutics

Day One

March 20, 2019

11.30 | Supercharging the Tumor Microenvironment: Lessons from NKTR-214 and Opdivo

Viviana Cremasco
Investigator
Novartis

Weiyi Peng
Instructor
University of Houston

Wim Van Schooten
Chief Scientific Officer
Teneobio

John Burke
President, Chief Executive Officer & Co-founder
Applied Biomath

Day One

March 20, 2019

09.40 | Model Aided Drug Invention Case Study: GITR-mediated T cell dynamics in Mouse Tumor Micro Environment

Paul Rennert
President and Chief Scientific Officer
Aleta Biotherapeutics

Day One

March 20, 2019

09.10 | Establishing a New Set of Biological Goals for Checkpoint Inhibitors and IO Combinations

Mark Yore
Manager of Corporate Development
Jounce Therapeutics

Day One

March 20, 2019

08.40 | Navigating the complex ICI-IO landscape – Recent updates and Future Challenges

Amy-Jo Casbon
Immunotherapy & Oncology Scientist
Amgen Inc.

Bei Wang
Staff Scientist
Regeneron

Day One

March 20, 2019

16.30 | T Cell Dysfunction and Combination Immunotherapy

Beth Trehu
Chief Medical Officer
Jounce Therapeutics

Day One

March 20, 2019

12.30 | Lessons Learned from a Clinical Trial Targeting ICOS

Bruno Osterwalder
Senior Vice President
BO Consulting

Day Two

March 21, 2019

14.45 | Panel Discussion – How Can We Sort Through the Huge Number of Trials that are Currently Active?

Catherine Sabatos-Peyton
Director
Novartis

Day Two

March 21, 2019

09.40 | Panel Discussion: Mind the Gap - Considering New Targets from Biological Rationale to Therapeutic Protein Delivery

Cedric Dos Santos
Principal Scientist - Heme, Oncology, Clinical Biomarkers & Therapeutic Areas Lead
Amgen Inc.

Eva Vanamee
Chief Scientific Officer
FusionBio

Day Two

March 21, 2019

09.40 | Panel Discussion: Mind the Gap - Considering New Targets from Biological Rationale to Therapeutic Protein Delivery

Hans Van Eenemann
Executive Vice President Antibody Research
Aduro Biotech

Day Two

March 21, 2019

13.45 | Innate Myeloid-Cell Inhibition: Explore the Capability of CD-27 Novel Checkpoint-Modulation as an Inhibitor